This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Combating Residual Risk with Treatment Intensification: Focus on PCSK9 Inhibitors - A Care Team Forum<sup style="font-size:14px;">SM</sup>

Combating Residual Risk with Treatment Intensification: Focus on PCSK9 Inhibitors - A Care Team ForumSM

Format

Expert Perspective

Time to Complete

30 minutes

Released

May 15, 2019

Expires

May 14, 2020
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

This activity is jointly provided by the National Lipid Association and RMEI Medical Education, LLC.

Commercial Supporter

This activity is supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.

Program Description

This activity features an engaging video panel discussion with 3 renowned clinical experts and Charles—a patient living with familial hypercholesterolemia (FH). The lively exchange is enhanced with explanatory visuals; direct note-taking capability; interactive questions; and a full in-suit resource library. The panel will delve into topics covering safety/efficacy data for PCSK9 inhibitors (PCSK9-Is), 2018 ACC/AHA guideline updates, and patient selection for treatment intensification with PCSK9-Is. Faculty will examine key matters in patient care, provide illustrative patient case scenarios, pose practical solutions to common issues encountered in clinical practice, and Charles will provide insight into his experience with FH, its treatment, and his interaction with the healthcare system.

Intended Audience

The target audience for this activity is lipidologists, endocrinologists, cardiologists, internal medicine and family medicine physicians, NPs, and PAs who manage patients with hypercholesterolemia.

Educational Objective

After completing this activity, the participant will demonstrate the ability to:

  • Use PCSK9 inhibitors to manage hypercholesterolemia based on patient characteristics, guidelines, MOA, and efficacy and safety data

Conflict Of Interest Disclosure Policy

This Conflict of Interest Policy of the National Lipid Association (NLA): (1) defines conflicts of interest; (2) identifies classes of individuals within the NLA covered by this policy; (3) facilitates disclosure of information that may help identify conflicts of interest; and (4) specifies procedures to be followed in managing conflicts of interest. Covered individuals should recognize that this Policy does not replace, but rather is in addition to, any and all Conflict of Interest policies adopted by the NLA to which they may be subject to including industry relationships, medical education or continuing medical education (CME), or other regulatory authority.

1. Definition of conflicts of interest. A conflict of interest occurs when an individual has both a financial relationship with a commercial interest, as defined by the Accreditation Council for Continuing Medical Education (ACCME), within the past 12 months and has the opportunity to affect content relevant to products or services of the commercial interest. Additionally, a conflict of interest occurs when a person in a position of authority over the NLA may benefit financially from a decision he/she could make in that capacity, including indirect benefits such as to family members or businesses with which the individual is closely associated. The NLA agrees with the definition of “commercial interest” by the ACCME as: “any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients.”

2. Individuals covered. It is the policy of the National Lipid Association to require that all Board members, committee members, planners, faculty, reviewers of CME activities, and staff to submit signed financial disclosure forms. The NLA will provide the information upon request and on any education programs in accordance with this policy.

3. Facilitation of disclosure. Persons covered by this policy will annually disclose or update to the Board of Directors of the NLA, on a form provided by the NLA, their interests that could give rise to conflicts of interest, such as direct and indirect financial relationships with a commercial interest within the past 12 months. Failure to comply in a timely manner may result in actions as described in Section 4 and, at minimum, make the person ineligible for any reimbursement of expenses in conjunction with official NLA business until the deficiency is resolved. Failure to comply in relation to a CME activity results in disqualification from participating in the activity.

4. Procedures to manage conflicts. For each interest disclosed to the Board of Directors, the Board will determine whether to: (a) take no action; (b) assure full disclosure to related entities beyond the Board of Directors and/or other individuals covered by or related this policy; (c) ask the person to recuse from participation in related discussions or decisions within the NLA; or (d) ask the person to resign from his or her position in the NLA or, if the person refuses to resign, become subject to the bylaws pertaining to removal of officers and directors. The NLA’s Executive Director will monitor NLA activity pursuant to this policy and is responsible for reporting any potential or the status of ongoing conflicts of interest to the Board of Directors in order to correctly adjudicate the matters in question and or seek the counsel of the NLA attorney to guide in such matters.

Faculty

Activity Chair
James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA
Clinical Assistant Professor of Medicine, NYU School of Medicine and
NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY

Dr. Underberg reports the following disclosures:
Advisory Boards: Akcea, Alexion, Ambry, Amgen, Invitae, Regeneron, Sanofi
Consulting: Amarin, Amgen
Contracted Research: Aegerion, Pfizer, Sanofi
Speakers’ Bureau: Alexion, Amarin, Amgen, Regeneron, Sanofi
Steering Committee Member: Aegerion LOWER Registry Trial

Christie M. Ballantyne, MD
Professor and Vice Chair of Research, Department of Medicine
Director, Center for Cardiometabolic Prevention
Chief, Sections of Cardiology and Cardiovascular Research
Baylor College of Medicine
Houston, TX

Dr. Ballantyne reports the following disclosures:
Contracted Research: Abbott Diagnostics, Akcea, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Consultant: Abbot Diagnostics, Akcea, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, Sanofi-Synthelabo

Gregory P. Hess, MD, MBA, MSc
Instructor, Department of Emergency Medicine
Drexel University College of Medicine
Adjunct Senior Fellow, Leonard Davis Institute for Health Economics
University of Pennsylvania
Philadelphia, PA

Dr. Hess reports the following disclosures:
Advisory Committee: Heron Therapeutics, US WorldMeds
Committee: Millennium Health
Contracted Research: Amgen & AstraZeneca through Symphony Health
Speakers’ Bureau: US WorldMeds

Patient Participant
Charles
(patient) has nothing to disclose.

Accredited Provider Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

National Lipid Association planners and managers have nothing to disclose.
The National Lipid Association’s Inter-Professional Continuing Education (ICE) Committee reviewer Casey Elkins, DNP, NP-C, CLS, FNLA, reports receiving an honorarium for speaking for Regeneron/Sanofi.

RMEI Medical Education, LLC planners and managers have nothing to disclose.

RMEI Medical Education's medical director, Lobna Eldasher, PharmD, has nothing to disclose.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by the National Lipid Association and RMEI Medical Education, LLC. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The NLA designates this internet enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit(s)TM  from organizations accredited by ACCME.

Nurse Practitioners
AANPCB accepts AMA PRA Category 1 Credit(s)TM  from organizations accredited by ACCME.

Fee Information

There is no fee for this educational activity.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

Instructions

To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your certificate will be saved in your CME History on myCME.

If you have any questions relating to the accreditation of this activity, please contact cme@lipid.org.
Add to Queue


Related to this activity